skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

K-111: the emerging evidence for its potential in the treatment of the metabolic syndrome

Review

(1830) Views  (511) Full article downloads

Authors: Margaret Duggan-Keen

Published Date March 2006 Volume 2006:1-Issues 3 & 4(3) Pages 0 - 0
DOI: http://dx.doi.org/10.2147/CE.S7444

Margaret Duggan-Keen

Core Medical Publishing, Knutsford, UK

Introduction: Prevalence of the metabolic syndrome has increased dramatically in recent years. Optimal patient care demands a multifaceted approach, with many individuals requiring several therapies to minimize the significant associated cardiovascular burden. The need for novel agents in the management of the metabolic syndrome is emphasized by the current lack of drugs to treat insulin resistance, one of the major components of the metabolic syndrome that has several deleterious consequences.

Aims: The objective of this review is to assess the emerging evidence for the potential use of K-111 in treatment of the metabolic syndrome.

Emerging evidence: K-111 is a peroxisome proliferator-activated receptor (PPAR)-alfa agonist that, in preclinical studies, has shown efficacy in improving insulin resistance, reducing bodyweight, and ameliorating atherogenic dyslipidemia. Preliminary evidence suggests that toxicity and adverse events are low.

Profile: The improvements in obesity and insulin resistance, together with other beneficial effects following activation of PPAR alfa by K-111 in preclinical models, are encouraging and offer several potential advantages over currently available therapies for patients with the metabolic syndrome. However, K-111 is at an early stage of development and establishment of its role will require full analysis of clinical trials carefully designed to determine its overall benefits in this increasingly important disease area.

Key words: BM 17.0744, cardiovascular diseases, insulin resistance, K-111, metabolic syndrome X, PPAR alfa






 

Other articles by Dr Core Journal

Aliskiren in hypertension: evidence for its potential therapeutic value
Aprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting
Aripiprazole: the evidence of its therapeutic impact in schizophrenia
Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer
Bortezomib: the evidence of its clinical impact in multiple myeloma
Ciclesonide in persistent asthma: the evidence of its therapeutic value
Dasatinib: the emerging evidence of its potential in the treatment of chronic myeloid leukemia
Donepezil in Alzheimer’s disease: an evidence-based review of its impact on clinical and economic outcomes
Dutasteride: an evidence-based review of its clinical impact in the treatment of benign prostatic hyperplasia
Eltrombopag: the emerging evidence of its therapeutic value in thrombocytopenia
Eplerenone: the evidence for its place in the treatment of heart failure after myocardial infarction
Etanercept in psoriasis: the evidence of its therapeutic impact
Exubera® (inhaled insulin): an evidence-based review of its effectiveness in the management of diabetes
Fosphenytoin for the treatment of status epilepticus: an evidence-based assessment of its clinical and economic outcomes
FTY720 in multiple sclerosis: the emerging evidence of its therapeutic value
Lapatinib: the evidence for its therapeutic value in metastatic breast cancer
Lumiracoxib: the evidence of its clinical impact on the treatment of osteoarthritis
Maraviroc: the evidence for its potential in the management of HIV
Perindopril: the evidence of its therapeutic impact in hypertension
Pramipexole in restless legs syndrome: an evidence-based review of its effectiveness on clinical outcomes
Rimonabant: the evidence for its use in the treatment of obesity and the metabolic syndrome
Sevelamer as a phosphate binder in adult hemodialysis patients: an evidence-based review of its therapeutic value
Tigecycline: an evidence-based review of its antibacterial activity and effectiveness in complicated skin and soft tissue and intraabdominal infections
Topiramate: the evidence for its therapeutic value in the prevention of migraine
Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus


Readers of this article also read:

Sevelamer as a phosphate binder in adult hemodialysis patients: an evidence-based review of its therapeutic value
Eplerenone: the evidence for its place in the treatment of heart failure after myocardial infarction
Tigecycline: an evidence-based review of its antibacterial activity and effectiveness in complicated skin and soft tissue and intraabdominal infections
Exacerbation rate, health status and mortality in COPD – a review of potential interventions
"Globalized public health.” A transdisciplinary comprehensive framework for analyzing contemporary globalization’s influences on the field of public health
Multiple sclerosis: patients’ information sources and needs on disease symptoms and management
Hepatitis C virus infection and risk of cancer: a population-based cohort study
Dealing with grief related to loss by death and chronic pain: Suggestions for practice. Part 2
Clinical and economic considerations of antiobesity treatment: a review of orlistat
Erratum
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University